department of neurology  
  neurology  
  Address: The Neurological Institute of New York, 710 West 168th Street, 3rd Floor, New York, NY 10032  
 
 
 

EFFECTS OF COENZYME Q10 IN PARKINSON'S DISEASE - QE3



» back to Clinical Research Studies

A study for People with Early Parkinson's disease who have not been treated or have been treated for 90 days or less

Sponsored by the Parkinson Study Group and is funded by the National Institute of Neurological Disorders and Stroke (NIND), a division of the National Institute of Health (NIH).



WHO IS ELIGIBLE


This study is for people who have early signs of Parkinson's disease. Eligible study participants have been diagnosed within the past 5 years and not on regular treatment for Parkinson's disease for more than 90 days.

WHAT IS THE PURPOSE


This is an experimental drug study testing whether the health food supplement, Coenzyme Q10, will slow the progressive impairment of Parkinson's disease. Study participants will be randomized in a 1:1:1 ratio: 2400 mg per day of Coenzyme Q10 or 1200mg per day of Coenzyme Q10 or matching placebo.

Randomized means that the choice of what study drug you get is done by a computer program. The study participant and the study team do not get to choose and actually will not know what the study participant is taking during the study. All participants will receive vitamin E 1200 IU per day, and a multi-vitamin (if desired).

WHAT IS THE DURATION


The study requires 7 visits within 17 months to our study research office located in the Neurological Institute at Columbia University Medical Center. At each study visit, the study doctor will interview and examine the study participants to be sure that they do not need to start regular treatment for Parkinson's disease. If such a need is determined, the study participant will leave the study in order to get the treatment they need. Visits include a comprehensive neurological assessment, complete blood work, and heart tracing, called an electrocardiogram (ECG).

If you are interested in knowing more about this clinical trial, please contact:

ANGEL FIGUEROA


Research Worker
212.305.6121
af2161@columbia.edu

ANI ARKUN


Clinical Trials Coordinator
212.305.6121
aa2089@columbia.edu



Sitemap | Email Comments

Copyright © 2004 The Neurological Institute of New York || Columbia University Medical Center || Division of Movement Disorders
Affiliated with New York-Presbyterian Hospital
710 W 168th St, New York, NY 10032
Last updated: July 17, 2013
 

ABOUT US:

- MISSION STATEMENT
- OUR DOCTORS
- CONTACT & DIRECTIONS
PATIENT INFORMATION:

- OUR DOCTORS
- CLINICAL CARE
- WHAT ARE MOVEMENT DIORDERS?
- CLINICAL RESEARCH STUDIES
- CLINICAL MOTOR PHYSIOLOGY LABORATORY
- MOVEMENT DISORDERS & FAMILY HISTORY
- MOVEMENT DISORDERS SURGERY CENTER
- BRAIN BANK
- CONTACT & DIRECTIONS

EDUCATION:

- MOVEMENT DISORDERS FELLOWSHIP
- FORMER AND CURRENT FELLOWS
RESEARCH:

- BASIC SCIENCE RESEARCH
- CLINICAL RESEARCH
- CLINICAL RESEARCH STUDIES
- GENETIC RESEARCH